Skip to main content

Migraine With Aura

Neurology
5
Pipeline Programs
7
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
3
0
Early DiscoveryClinical DevelopmentMarket

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.6yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Lotus Pharmaceuticals
Lotus PharmaceuticalsTaiwan - Taipei
1 program
1
Laxymig ERPhase 31 trial
Active Trials
NCT00334178Completed74Est. Sep 2006
MSD
MSDIreland - Ballydine
1 program
1
Maxalt 10mg MLT plus Caffeine 75mgPhase 31 trial
Active Trials
NCT00471952Completed50Est. Apr 2008
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Maxalt 10mg MLT plus Caffeine 75mgPhase 3
Dr. Reddy's Laboratories
1 program
1
DFN-15Phase 21 trial
Active Trials
NCT03472378Completed51Est. Apr 2019
Satsuma Pharmaceuticals
1 program
1
DihydroergotaminePhase 11 trial
Active Trials
NCT03874832Completed46Est. Nov 2018
Theranica
TheranicaNJ - Bridgewater
1 program
Nerivio deviceN/A1 trial
Active Trials
NCT06023953Completed31,715Est. Dec 2024
Nektar Therapeutics
Nektar TherapeuticsSAN FRANCISCO, CA
1 program
Dronabinol MDIPHASE_21 trial
Active Trials
NCT00123201CompletedEst. Mar 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MSDMaxalt 10mg MLT plus Caffeine 75mg
Lotus PharmaceuticalsLaxymig ER
Dr. Reddy's LaboratoriesDFN-15
Nektar TherapeuticsDronabinol MDI
Satsuma PharmaceuticalsDihydroergotamine
TheranicaNerivio device

Clinical Trials (6)

Total enrollment: 31,936 patients across 6 trials

NCT00471952MSDMaxalt 10mg MLT plus Caffeine 75mg

Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache

Start: Apr 2007Est. completion: Apr 200850 patients
Phase 3Completed

Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine

Start: Nov 2004Est. completion: Sep 200674 patients
Phase 3Completed

Can DFN-15 Terminate Migraine With Allodynia?

Start: May 2018Est. completion: Apr 201951 patients
Phase 2Completed

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

Start: Sep 2005Est. completion: Mar 2007
Phase 2Completed

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

Start: Sep 2018Est. completion: Nov 201846 patients
Phase 1Completed
NCT06023953TheranicaNerivio device

Migraine With and Without Aura Characteristics and Response to Remote Electrical Neuromodulation (REN) Treatment

Start: Jul 2023Est. completion: Dec 202431,715 patients
N/ACompleted

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.